In 2023, Intra-Cellular Therapies completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources).
However, Intra-Cellular Therapies has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
In 2023, the total operational greenhouse gas (GHG) emissions of Intra-Cellular Therapies amounted to 3,907 metric tons of CO2 equivalent. This figure reflects direct emissions from owned or controlled sources (Scope 1).
In 2023, the total Scope 1 emissions of Intra-Cellular Therapies were 3,907 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).